Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.

AIDS (London, England) - 10 Sept 2009

De Meyer Sandra, Lathouwers Erkki, Dierynck Inge, De Paepe Els, Van Baelen Ben, Vangeneugden Tony, Spinosa-Guzman Sabrina, Lefebvre Eric, Picchio Gaston, de Béthune Marie-Pierre

Abstract excerpt

OBJECTIVE: Characterization of resistance development in virologic failure patients on the protease inhibitor darunavir administered with low-dose ritonavir (DRV/r) in the 48-week analysis of TMC114/r In Treatment-experienced pAtients Naive to lopinavir (TITAN). DESIGN: TITAN is a randomized, controlled, open-label, phase III, noninferiority trial comparing the efficacy and safety of DRV/r with that of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Darunavir
Share to Drug Resistance, Multiple, Viral

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to HIV Protease Inhibitors

Share to Lopinavir

Share to Pyrimidinones

Share to Reverse Transcriptase Inhibitors

Share to Ritonavir

Share to Treatment Failure

Source

Identifiers

PMID: 19474650
DOI: 10.1097/QAD.0b013e32832cbcec

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.PMID 19474650Read ↗

Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.Semantic proximity Read ↗

Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patients.Semantic proximity Read ↗

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.Semantic proximity Read ↗

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis.Semantic proximity Read ↗

Clinical Outcomes Associated With Once-Daily Ritonavir-Boosted Darunavir Plus Tenofovir/Emtricitabine in HIV-Infected Patients Harboring at Minimum a M184V/I Resistance Mutation.Semantic proximity Read ↗

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.Semantic proximity Read ↗

Drug Susceptibility and Resistance Mutations After First-Line Failure in Resource Limited SettingsSemantic proximity Read ↗

Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.Semantic proximity Read ↗

Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.Semantic proximity Read ↗

Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.Semantic proximity Read ↗

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).Semantic proximity Read ↗

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.